Target intelligence / Profile preview

Schistosoma mansoni calpain large subunit (SmCalp1 (also known as Sm-p80))

Target
SmCalp1 (also known as Sm-p80)
Molecular classification
Enzyme, Cysteine protease, Calcium-dependent cysteine protease, Calpain family
01

Overview

The Schistosoma mansoni calpain large subunit is a calcium-dependent cysteine protease forming part of a heterodimeric enzyme complex critical for parasite survival. Two homologs, SmCalp1 (also known as Sm-p80) and SmCalp2, are present in the S. mansoni surface (tegument), with SmCalp1 being extensively characterized. This subunit contains characteristic protease domains (PC1, PC2), a membrane association domain (CBSW), and a C-terminal calcium-binding domain (PEF), all required for catalytic activity and substrate binding. Schistosome calpains degrade host proteins, such as fibronectin, contributing to immune evasion, survival, and possibly blood feeding. Targeting the large subunit with inhibitors like E64c impairs parasite viability, underscoring its therapeutic relevance and making it a target of transmission-blocking vaccines and diagnostic efforts.

Other names
SmCalp1Sm-p80Calpain large subunit (S. mansoni)Smp_214190 (gene annotation for SmCalp1)Smp_157500 (previous gene annotation for SmCalp1)Calpain catalytic domain-containing protein
02

Mechanism of action

Inhibition of protease activity, leading to interference with parasite survival or maintenance of host interaction surface

03

Biological functions

Proteolysis of host and parasite proteinsCalcium-dependent protein cleavagePossible involvement in cell signaling and cytoskeletal remodelingModulation of host-pathogen interactions at the host-parasite interface
04

Disease associations

Infection (schistosomiasis, caused by Schistosoma mansoni)Immune evasion by the parasitePotential involvement in resistance or susceptibility to antiparasitic therapy
05

Safety considerations

Cross-reactivity with host calpains or conserved domains may cause adverse effects if targeted therapeuticallyDifficulty in achieving parasite-specific inhibition due to structural conservation among calpains across species
06

Interacting drugs

E64c (a cysteine protease inhibitor shown to inhibit SmCalp1/SmCalp2 activity)

1 more in the full profile.

07

Biomarkers

Sm-p80 (calpain large subunit antigen, studied as a vaccine candidate and potential diagnostic marker for S. mansoni infection)

Beyond the preview

Go deeper on Schistosoma mansoni calpain large subunit (SmCalp1 (also known as Sm-p80)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schistosoma mansoni calpain large subunit (SmCalp1 (also known as Sm-p80)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call